IS4891A - Samsetningar til meðhöndlunar einu sinni á dag á sjúkdómum sem eru háðir sýklóoxýgenasa-2 - Google Patents

Samsetningar til meðhöndlunar einu sinni á dag á sjúkdómum sem eru háðir sýklóoxýgenasa-2

Info

Publication number
IS4891A
IS4891A IS4891A IS4891A IS4891A IS 4891 A IS4891 A IS 4891A IS 4891 A IS4891 A IS 4891A IS 4891 A IS4891 A IS 4891A IS 4891 A IS4891 A IS 4891A
Authority
IS
Iceland
Prior art keywords
cyclooxygenase
compositions
once
dependent diseases
daily treatment
Prior art date
Application number
IS4891A
Other languages
English (en)
Inventor
Hancock Bruno
Winters Conrad
Gertz Barry
Ehrich Elliot
Original Assignee
Merck & Co., Inc.
Merck Frosst Company.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS4891(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Application filed by Merck & Co., Inc., Merck Frosst Company. filed Critical Merck & Co., Inc.
Publication of IS4891A publication Critical patent/IS4891A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
IS4891A 1996-05-17 1998-11-10 Samsetningar til meðhöndlunar einu sinni á dag á sjúkdómum sem eru háðir sýklóoxýgenasa-2 IS4891A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
PCT/US1997/008041 WO1997044028A1 (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Publications (1)

Publication Number Publication Date
IS4891A true IS4891A (is) 1998-11-10

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4891A IS4891A (is) 1996-05-17 1998-11-10 Samsetningar til meðhöndlunar einu sinni á dag á sjúkdómum sem eru háðir sýklóoxýgenasa-2

Country Status (28)

Country Link
US (1) US6063811A (is)
EP (1) EP0910368A1 (is)
JP (1) JPH11512754A (is)
KR (1) KR100373622B1 (is)
CN (1) CN1140267C (is)
AR (1) AR012014A1 (is)
AU (1) AU3004997A (is)
BG (1) BG103000A (is)
BR (1) BR9709097A (is)
CA (1) CA2254061C (is)
CO (1) CO5050370A1 (is)
CZ (1) CZ291463B6 (is)
DZ (1) DZ2200A1 (is)
EA (1) EA001596B1 (is)
EE (1) EE03746B1 (is)
HR (1) HRP970262A2 (is)
HU (1) HUP9902889A3 (is)
ID (1) ID16921A (is)
IL (1) IL126899A (is)
IS (1) IS4891A (is)
MY (1) MY116201A (is)
NO (1) NO985342D0 (is)
NZ (1) NZ332670A (is)
PE (1) PE66998A1 (is)
PL (1) PL188649B1 (is)
SK (1) SK284330B6 (is)
TR (1) TR199802345T2 (is)
WO (1) WO1997044028A1 (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
WO1999045913A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Combination therapy and composition for acute coronary ischemic syndrome and related conditions
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
CN1434713A (zh) * 1999-12-22 2003-08-06 法马西亚公司 环加氧酶－2抑制剂的缓释制剂
ATE511844T1 (de) 2000-06-13 2011-06-15 Wyeth Llc Analgetische und entzündungshemmende zusammensetzungen enthaltend celecoxib und ibuprofen
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
DE60120710T2 (de) * 2000-08-18 2007-06-14 Pharmacia Corp. Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
US8680081B2 (en) * 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2445502A1 (en) * 2001-05-04 2002-11-14 Merck & Co., Inc. Method and compositions for treating migraines
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
CN1633281A (zh) * 2001-09-26 2005-06-29 法马西亚公司 口内崩解的伐地考昔组合物
EP1450769A1 (en) * 2001-10-10 2004-09-01 Pharmacia Corporation Intraorally disintegrating valdecoxib compositions prepared by spray drying process
CA2476744A1 (en) * 2002-03-07 2003-09-12 Novartis Ag Solid pharmaceutical compositions comprising lumiracoxib
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ATE342722T1 (de) 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
EP2114461A2 (en) * 2007-01-19 2009-11-11 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
MX2021005967A (es) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Formas purificadas de rofecoxib, métodos de fabricación y uso.
WO2020210373A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CN1143365A (zh) * 1994-01-10 1997-02-19 麦克弗罗斯特(加拿大)有限公司 作为cox-2抑制剂的苯基杂环类化合物

Also Published As

Publication number Publication date
KR100373622B1 (ko) 2003-07-12
HUP9902889A3 (en) 2002-04-29
PL329940A1 (en) 1999-04-26
AU3004997A (en) 1997-12-09
CA2254061A1 (en) 1997-11-27
NZ332670A (en) 2000-07-28
CZ373898A3 (cs) 1999-06-16
DZ2200A1 (fr) 2004-06-20
BG103000A (en) 1999-09-30
SK156798A3 (en) 2000-01-18
CA2254061C (en) 2003-12-02
NO985342L (no) 1998-11-16
PL188649B1 (pl) 2005-03-31
AR012014A1 (es) 2000-09-27
SK284330B6 (sk) 2005-01-03
CO5050370A1 (es) 2001-06-27
TR199802345T2 (xx) 1999-03-22
EE03746B1 (et) 2002-06-17
US6063811A (en) 2000-05-16
CN1225010A (zh) 1999-08-04
IL126899A (en) 2004-03-28
EP0910368A1 (en) 1999-04-28
JPH11512754A (ja) 1999-11-02
ID16921A (id) 1997-11-20
EE9800393A (et) 1999-06-15
HUP9902889A2 (hu) 2002-01-28
HRP970262A2 (en) 1998-06-30
PE66998A1 (es) 1998-10-24
IL126899A0 (en) 1999-09-22
CN1140267C (zh) 2004-03-03
EA199801017A1 (ru) 1999-04-29
WO1997044028A1 (en) 1997-11-27
KR20000011082A (ko) 2000-02-25
BR9709097A (pt) 1999-08-03
HK1021623A1 (en) 2000-06-23
CZ291463B6 (cs) 2003-03-12
NO985342D0 (no) 1998-11-16
MY116201A (en) 2003-11-28
EA001596B1 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
IS4891A (is) Samsetningar til meðhöndlunar einu sinni á dag á sjúkdómum sem eru háðir sýklóoxýgenasa-2
IL121170A0 (en) Compositions for the treatment of dermatological disorders
DE69700723D1 (de) Behandlung für Formgedächtnislegierung
ATE231724T1 (de) Kombinationstherapie für die behandlung von psychosen
EP0792137A4 (en) ANTIMYCOSIC TREATMENT FOR NAILS
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
FI952721A7 (fi) Aine maksa-sappi-sairauksien hoitamiseksi
DE69509650D1 (de) Behandlung atrialer fibrillationen
BR9708601A (pt) Tratamento de uma hemoglobinopatia
DK0835637T3 (da) Behandlingstilbehør til endeskop
DK0834278T3 (da) Behandlingstilbehør til endoskop
EP1017402A4 (en) INTESTINAL ACID SYNDROME THERAPY
EP1109453A4 (en) COMPOSITIONS AND METHOD FOR TREATING MITOCHONDRIAL DISEASES
HU9700163D0 (en) Use of droloxifene for treatment of cardiovascular diseases
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
ITTO940748A0 (it) Condotto protesico particolarmente per il trattamento di patologie cardiovascolari.
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
NO984432D0 (no) FremgangsmÕte for behandling av migrenesmerte
HUP0000954A3 (en) Medicinal compositions for treating cardiac diseases caused by cardiac hypertrophy
IL113057A0 (en) Compositions for the treatment of dandruff
NO982562D0 (no) Sammensetning for behandling av smerte
GB9510162D0 (en) Compositions for the treatment of skin conditions
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose